Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Tegaserod for improvement of upper-GI symptoms in patients with functional heartburn

Tegaserod significantly improves esophageal mechanical pain threshold, regurgitation, and global preference vs. placebo in patients with functional heartburn, suggests a study in the July issue of Gastroenterology.

News image

fiogf49gjkf04

Tegaserod is a 5-HT4 receptor partial agonist that is used to effectively treat constipation-predominant irritable bowel syndrome.

It works by enhancing gastrointestinal motility and reducing visceral pain.

It is believed that through its neuromodulatory action, Tegaserod may also improve the symptoms of functional heartburn, by the same mechanisms within the esophagus.

Researchers from the Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, USA, therefore set out to determine if this was the case.

The scientists investigated whether Tegaserod given at 6 mg BID could do any of 3 things in patients with functional heartburn.

They compared Tegaserod to a placebo in these patients to see if the treatment could; raise esophageal pain threshold to mechanical and chemical stimuli, improve upper and lower GI symptom profile (occurrence, frequency, severity and distress), and increase global preference compared to the placebo.

Seventy patients who had given informed consent were screened, from which 42 evaluable patients with heartburn were obtained (15 male, 27 female, age range 20 – 68 years).

At screening the patients underwent esophageal manometry, 24-hour pH-metry, esophageal gastroduodenoscopy, esophageal balloon distention and Bernstein acid infusion.

Treatment with Tegaserod was associated with a higher rate of diarrhea
Gastroenterology

Study patients were then randomly assigned to Tegaserod 6 mg BID and placebo for 14 consecutive days, in a crossover design, separated by a 7 – 10 day washout period.

After each treatment regimen, patients underwent esophageal acid infusion and balloon distention and also completed a GI multi-symptom questionnaire, with occurrence, frequency, severity and level of distress collected for each symptom.

Following completion of the study, patients were asked to rate their preference for overall treatment regimen.

The study showed that Tegaserod significantly increased both the balloon pressure and balloon volume required to induce pain.

The mean and the maximum wall tension of the balloon at the pain threshold were also increased with Tegaserod.

Tegaserod had no effect on pain threshold to acid infusion.

However, there was a significant decrease in occurrence of heartburn/acid reflux and regurgitation, as well as a reduction in the level of distress perceived from the regurgitation, when Tegaserod was used.

Treatment with Tegaserod was associated with a higher rate of diarrhea, but despite this, no withdrawals from treatment took place as a result of this side effect.

Global treatment preference was 63.4% for tegaserod, and 12.2% for placebo. 24.4% of patients had no treatment preference.

Concluding on behalf of his fellow authors, S. Rodriguez-Stanley said, "Tegaserod significantly improved esophageal pain threshold to mechanical distention; however, tegaserod did not alter acid sensitivity."

He continued, "This supports separate chemical and mechanical pain pathways in the esophagus, " and added, "Tegaserod improved distressing upper GI symptoms in patients with functional heartburn, particularly regurgitation."

Gastroenterology 2004; 127 (1): 331
09 July 2004

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us